 |
SEOUL, South Korea, May 20, 2026 /PRNewswire/ — Hyundai Bioscience announced on May 19th that it can supply clinical trial doses of its broad-spectrum antiviral drug XAFTY® in response to growing global concern over infectious disease outbreaks caused by Ebola and hantavirus.
Hyundai Bioscience said that if the World Health Organization (WHO) or countries affected by infectious disease outbreaks request support for XAFTY®, it can immediately provide products currently in stock.
According to the company, niclosamide, the main ingredient of XAFTY®, has previously been reported to have inhibitory effects against Ebola and hantavirus.
The company stated, “In the ongoing Phase 2 clinical trial of XAFTY® for dengue fever in Vietnam, no adverse events have been reported so far,” and claimed that “in a situation where two viruses are spreading simultaneously, XAFTY® could serve as an effective alternative.”
Hyundai Bioscience added that, as a member of the Medical CBRN Defense Consortium (MCDC), a U.S. Department of Defense-supported consortium, it will actively cooperate in responding to international public health crises.
CONTACT：
Jason Kim
[email protected]
(562) 964-3910
ข่าวที่เกี่ยวข้อง
- QBit Semiconductor Shares Surge to USD$18 on Debut, Driving Market Capitalization to USD$700 Million
- Kong Partners with Unfold to Accelerate Channel Growth Across Australia and New Zealand
- P & A Link Strengthens Its Position as an Integrated Commercial Interior Design and Fit-Out Partner Across Asia
- รายงานของ HCLTech เตือนว่าโครงการ AI ในองค์กรราว 43% อาจล้มเหลว เนื่องจากผู้นำองค์กรเผชิญกับกรอบเวลาที่สั้นลงในการสร้างผลลัพธ์
